QQQ   308.18 (+0.72%)
AAPL   158.64 (+0.79%)
MSFT   271.07 (-0.43%)
META   200.12 (+1.17%)
GOOGL   104.62 (+3.36%)
AMZN   99.81 (+2.15%)
TSLA   195.41 (+6.64%)
NVDA   261.65 (+1.02%)
NIO   9.29 (+6.17%)
BABA   83.32 (+2.86%)
AMD   95.87 (-0.97%)
T   18.46 (-0.16%)
F   11.68 (+4.47%)
MU   58.18 (+0.94%)
CGC   1.98 (+6.45%)
GE   92.50 (+2.87%)
DIS   96.12 (+2.02%)
AMC   4.38 (+2.58%)
PFE   40.36 (-1.10%)
PYPL   75.79 (+3.52%)
NFLX   304.31 (-0.27%)
QQQ   308.18 (+0.72%)
AAPL   158.64 (+0.79%)
MSFT   271.07 (-0.43%)
META   200.12 (+1.17%)
GOOGL   104.62 (+3.36%)
AMZN   99.81 (+2.15%)
TSLA   195.41 (+6.64%)
NVDA   261.65 (+1.02%)
NIO   9.29 (+6.17%)
BABA   83.32 (+2.86%)
AMD   95.87 (-0.97%)
T   18.46 (-0.16%)
F   11.68 (+4.47%)
MU   58.18 (+0.94%)
CGC   1.98 (+6.45%)
GE   92.50 (+2.87%)
DIS   96.12 (+2.02%)
AMC   4.38 (+2.58%)
PFE   40.36 (-1.10%)
PYPL   75.79 (+3.52%)
NFLX   304.31 (-0.27%)
QQQ   308.18 (+0.72%)
AAPL   158.64 (+0.79%)
MSFT   271.07 (-0.43%)
META   200.12 (+1.17%)
GOOGL   104.62 (+3.36%)
AMZN   99.81 (+2.15%)
TSLA   195.41 (+6.64%)
NVDA   261.65 (+1.02%)
NIO   9.29 (+6.17%)
BABA   83.32 (+2.86%)
AMD   95.87 (-0.97%)
T   18.46 (-0.16%)
F   11.68 (+4.47%)
MU   58.18 (+0.94%)
CGC   1.98 (+6.45%)
GE   92.50 (+2.87%)
DIS   96.12 (+2.02%)
AMC   4.38 (+2.58%)
PFE   40.36 (-1.10%)
PYPL   75.79 (+3.52%)
NFLX   304.31 (-0.27%)
QQQ   308.18 (+0.72%)
AAPL   158.64 (+0.79%)
MSFT   271.07 (-0.43%)
META   200.12 (+1.17%)
GOOGL   104.62 (+3.36%)
AMZN   99.81 (+2.15%)
TSLA   195.41 (+6.64%)
NVDA   261.65 (+1.02%)
NIO   9.29 (+6.17%)
BABA   83.32 (+2.86%)
AMD   95.87 (-0.97%)
T   18.46 (-0.16%)
F   11.68 (+4.47%)
MU   58.18 (+0.94%)
CGC   1.98 (+6.45%)
GE   92.50 (+2.87%)
DIS   96.12 (+2.02%)
AMC   4.38 (+2.58%)
PFE   40.36 (-1.10%)
PYPL   75.79 (+3.52%)
NFLX   304.31 (-0.27%)
NASDAQ:SRRA

Sierra Oncology - SRRA Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$54.99
▼
$54.99
50-Day Range
$54.73
▼
$54.99
52-Week Range
$14.91
▼
$55.19
Volume
N/A
Average Volume
931,731 shs
Market Capitalization
$1.34 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$55.00

SRRA stock logo

About Sierra Oncology (NASDAQ:SRRA) Stock

Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California.

Receive SRRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sierra Oncology and its competitors with MarketBeat's FREE daily newsletter.

SRRA Stock News Headlines

February 25, 2023 | benzinga.com
Celyad Oncology Stock (NASDAQ:CYAD), Quotes and News Summary
January 20, 2023 | finance.yahoo.com
Interventional Oncology Global Market - Forecast To 2029
March 21, 2023 | PressReach (Ad)
Stocks Positioned For The Year
This breakthrough stock has bright future this decade.
January 5, 2023 | nasdaq.com
GSK Signs Deal to Develop Antibodies for Treating Cancer
October 12, 2022 | marketwatch.com
Sareum Holdings Says Sierra Oncology To Return Cancer Treatment License; Shares Fall
September 25, 2022 | marketwatch.com
Companion Diagnostic Tests in Oncology Market 2022 Key Product Segments, Application Analysis, and Industry Growth Forecast by 2027
September 1, 2022 | thestreet.com
15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies
July 4, 2022 | marketwatch.com
Sareum Holdings Says GSK Completes Acquisition of Sierra Oncology
March 21, 2023 | PressReach (Ad)
Stocks Positioned For The Year
This breakthrough stock has bright future this decade.
June 17, 2022 | finance.yahoo.com
Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration
June 13, 2022 | uk.finance.yahoo.com
Sierra Oncology hits 52w high – but will it continue?
May 26, 2022 | finance.yahoo.com
Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting
May 12, 2022 | finance.yahoo.com
Sierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual Meeting
May 6, 2022 | finance.yahoo.com
Sierra Oncology Reports First Quarter 2022 Results
April 14, 2022 | msn.com
Biotech Stock Roundup: SRRA Surges on GSK Buyout, HALO Offers Update & More
April 14, 2022 | msn.com
Analyzing Sierra Oncology Inc's Short Interest
April 14, 2022 | markets.businessinsider.com
Analyst Ratings for Sierra Oncology
April 13, 2022 | finance.yahoo.com
GlaxoSmithKline Scoops Up Rare Cancer-Focused Sierra Oncology In $1.9B Cash Deal
April 13, 2022 | markets.businessinsider.com
Sierra Oncology Stock Is Soaring: Here's Why
April 13, 2022 | investorplace.com
Why Is Sierra Oncology (SRRA) Stock Up Today?
April 13, 2022 | msn.com
GlaxoSmithKline to buy Sierra Oncology for $1.9 billion
April 13, 2022 | finance.yahoo.com
GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bn
April 13, 2022 | nasdaq.com
GSK Agrees To Acquire Sierra Oncology For $1.9 Bln
April 13, 2022 | tmcnet.com
SRRA Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Sierra Oncology, Inc. Is Fair to Shareholders
April 13, 2022 | reuters.com
GSK to buy Sierra Oncology for $1.9 bln in boost to blood cancer ops
April 13, 2022 | barrons.com
Sierra Oncology Stock Soars After $1.9 Billion Takeover by GlaxoSmithKline
April 13, 2022 | finance.yahoo.com
Sierra Oncology Stock Soars After $1.9 Billion Takeover by Glaxo
See More Headlines
Receive SRRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sierra Oncology and its competitors with MarketBeat's FREE daily newsletter.

SRRA Company Calendar

Last Earnings
11/05/2021
Today
3/21/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SRRA
Previous Symbol
NASDAQ:DNAI
CUSIP
N/A
CIK
1290149
Web
www.sierraoncology.com
Phone
(604) 558-6536
Fax
N/A
Employees
109
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$55.00
High Stock Price Forecast
$55.00
Low Stock Price Forecast
$55.00
Forecasted Upside/Downside
+0.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($6.77)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-94,660,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-111.88%
Return on Assets
-100.01%

Debt

Debt-to-Equity Ratio
0.02
Current Ratio
21.27
Quick Ratio
21.27

Sales & Book Value

Annual Sales
$300,000.00
Price / Sales
4,476.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.16 per share
Price / Book
8.93

Miscellaneous

Outstanding Shares
24,419,000
Free Float
13,650,000
Market Cap
$1.34 billion
Optionable
Optionable
Beta
0.03

Key Executives

  • Dr. Stephen George Dilly M.B.B.S (Age 62)
    Pres, CEO & Director
    Comp: $1.02M
  • Mr. Sukhi Jagpal CPA (Age 48)
    CA, CBV, CPA, M.B.A., MBA, Chief Financial Officer
    Comp: $648.02k
  • Dr. Barbara J. Klencke M.D. (Age 65)
    Chief Medical Officer
    Comp: $773.39k
  • Ms. Christina Thomson J.D. (Age 51)
    M.S., Gen. Counsel, Chief Compliance Officer & Sec.
  • Mr. William D. TurnerMr. William D. Turner (Age 56)
    Chief Regulatory & Technical Operations Officer
  • Mr. Kevin Norrett M.B.A. (Age 49)
    M.S., Chief Bus. Officer

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













SRRA Stock - Frequently Asked Questions

Should I buy or sell Sierra Oncology stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sierra Oncology in the last twelve months. There are currently 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SRRA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SRRA, but not buy additional shares or sell existing shares.
View SRRA analyst ratings or view top-rated stocks.

What is Sierra Oncology's stock price forecast for 2023?

4 brokerages have issued twelve-month price objectives for Sierra Oncology's stock. Their SRRA share price forecasts range from $55.00 to $55.00. On average, they expect the company's stock price to reach $55.00 in the next year. This suggests a possible upside of 0.0% from the stock's current price.
View analysts price targets for SRRA or view top-rated stocks among Wall Street analysts.

How were Sierra Oncology's earnings last quarter?

Sierra Oncology, Inc. (NASDAQ:SRRA) released its quarterly earnings results on Friday, November, 5th. The biotechnology company reported ($2.10) EPS for the quarter, missing analysts' consensus estimates of ($1.78) by $0.32.

What other stocks do shareholders of Sierra Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sierra Oncology investors own include VBI Vaccines (VBIV), T2 Biosystems (TTOO), Co-Diagnostics (CODX), Tonix Pharmaceuticals (TNXP), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), Actinium Pharmaceuticals (ATNM), OPKO Health (OPK), Sorrento Therapeutics (SRNE) and Biocept (BIOC).

What is Sierra Oncology's stock symbol?

Sierra Oncology trades on the NASDAQ under the ticker symbol "SRRA."

What is Sierra Oncology's stock price today?

One share of SRRA stock can currently be purchased for approximately $54.99.

How much money does Sierra Oncology make?

Sierra Oncology (NASDAQ:SRRA) has a market capitalization of $1.34 billion and generates $300,000.00 in revenue each year. The biotechnology company earns $-94,660,000.00 in net income (profit) each year or ($6.77) on an earnings per share basis.

How many employees does Sierra Oncology have?

The company employs 109 workers across the globe.

How can I contact Sierra Oncology?

Sierra Oncology's mailing address is 2150-885 WEST GEORGIA STREET, VANCOUVER A1, V6C 3E8. The official website for the company is www.sierraoncology.com. The biotechnology company can be reached via phone at (604) 558-6536 or via email at investors@sierraoncology.com.

This page (NASDAQ:SRRA) was last updated on 3/21/2023 by MarketBeat.com Staff